Threonine is an essential amino acid that is the primary substrate for the synthesis of the mucin glycoproteins that coat and protect the gastrointestinal tract — the layer of mucus that covers the intestinal epithelium and that represents the first line of defence against the gastric acid, the digestive enzymes, and the bacterial antigens that are present in the gut lumen. The mucin glycoproteins are large, heavily O-glycosylated proteins that are synthesised and secreted by the goblet cells of the intestinal epithelium and by the specialised mucin-secreting cells of the stomach. They form a physical barrier that separates the intestinal epithelium from the gut lumen, preventing the direct contact of bacteria, food antigens, and digestive enzymes with the epithelial cells that line the gut. Threonine is the most abundant amino acid in mucin — it constitutes approximately 25-30% of the amino acids in the mucin glycoprotein backbone — and without adequate threonine, mucin synthesis is impaired, the mucus barrier is weakened, and the gut epithelium is more vulnerable to damage from gastric acid, digestive enzymes, and bacterial invasion.
The Gut Mucus Barrier
The gut mucus barrier consists of two layers: an outer loosely adherent layer that is colonised by the commensal bacteria of the gut microbiota, and an inner firmly adherent layer that is sterile and that provides the primary physical separation between the gut epithelium and the bacterial population of the gut lumen. The inner mucus layer is renewed daily by the secretion of mucin glycoproteins from the goblet cells of the intestinal epithelium — a process that requires adequate threonine availability for the synthesis of the mucin protein backbone. When threonine is deficient, mucin synthesis is impaired, the inner mucus layer becomes thinner and more permeable, and the risk of bacterial translocation (the passage of bacteria across the gut epithelium into the bloodstream) increases. This threonine-dependent vulnerability of the gut mucus barrier is one of the most important mechanisms of gut barrier dysfunction in malnutrition, in critical illness, and in the chronic inflammatory conditions that are characterised by a damaged or depleted mucus barrier.
Threonine and Inflammatory Bowel Disease
The clinical importance of the mucus barrier is underscored by the conditions that are characterised by its disruption — particularly the inflammatory bowel diseases (IBD), Crohn disease and ulcerative colitis, which are characterised by a thinner, more permeable, and less protective mucus barrier that allows direct contact between the gut bacteria and the intestinal epithelium, triggering the chronic inflammation that is the hallmark of these conditions. Studies in animal models of IBD show that threonine supplementation improves mucin synthesis, restores the inner mucus layer to its normal thickness, and reduces the severity of colitis — findings that are consistent with the threonine dependency of mucin synthesis and with the threonine deficiency that has been documented in patients with Crohn disease and ulcerative colitis.
Threonine and Protein Phosphorylation
Beyond its role in mucin synthesis, threonine is also an essential component of many other proteins in the body — it is incorporated into proteins at positions where it cannot be replaced by any other amino acid, and its side chain hydroxyl group is the site of important post-translational modifications (including phosphorylation by protein kinases, which is one of the most common mechanisms of enzyme regulation in the cell). The phosphorylation of threonine residues on proteins by threonine kinases (such as the MAP kinases, the CDKs, and the PKC family) is one of the primary mechanisms of signal transduction in the cell — it is the mechanism by which extracellular signals (growth factors, hormones, cytokines) are transmitted from the cell membrane to the nucleus and to the effector proteins that carry out the cellular response. When threonine residues on these proteins are phosphorylated, the activity of the protein is modified — some proteins are activated by threonine phosphorylation, others are inhibited. This threonine-dependent regulation of protein function is one of the most important mechanisms of cellular signalling and is the basis for the action of many oncogenic kinases that are constitutively activated in cancer cells.
Practical Application
For gut barrier support, the evidence-based dose is 1-3g of threonine daily from L-threonine. The primary clinical indications for threonine supplementation are gut barrier dysfunction (particularly in IBD, where threonine deficiency is common and where supplementation has been shown to improve mucus barrier integrity), and the general maintenance of the mucus barrier in people with chronic GI inflammation. For comprehensive gut health support, threonine pairs well with glutamine (which is the primary fuel source for the enterocytes that line the gut), with zinc carnosine (for gut lining integrity), with probiotics (for the restoration of the commensal bacteria that support gut barrier function), with deglycyrrhizinated licorice (DGL, for mucosal protection), and with the omega-3 fatty acids (for the resolution of chronic gut inflammation that is associated with increased intestinal permeability).
Leave a Reply